Inogen, Inc (NASDAQ:INGN) hit a new 52-week high during trading on Wednesday . The company traded as high as $98.78 and last traded at $98.78, with a volume of 101,440 shares trading hands. The stock had previously closed at $97.33.

A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Needham & Company LLC increased their price objective on shares of Inogen from $96.00 to $108.00 and gave the company a “strong-buy” rating in a research note on Friday, June 9th. BidaskClub raised shares of Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 8th. Stifel Nicolaus increased their price objective on shares of Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Finally, J P Morgan Chase & Co increased their price objective on shares of Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $91.60.

The company’s 50 day moving average price is $94.39 and its 200 day moving average price is $85.84. The firm has a market cap of $2.04 billion, a PE ratio of 85.40 and a beta of 1.02.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.10. The company had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. Inogen’s revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.25 earnings per share. Equities analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current year.

In related news, Director Raymond Huggenberger sold 15,300 shares of Inogen stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $90.88, for a total value of $1,390,464.00. Following the sale, the director now owns 7,808 shares of the company’s stock, valued at approximately $709,591.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $92.45, for a total value of $231,125.00. Following the completion of the sale, the executive vice president now directly owns 6,964 shares in the company, valued at approximately $643,821.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,467 shares of company stock worth $5,288,415. 5.31% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in Inogen in the 2nd quarter valued at approximately $442,000. Koch Industries Inc. raised its position in Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after buying an additional 653,747 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Inogen in the 2nd quarter valued at approximately $280,000. Piedmont Investment Advisors LLC acquired a new stake in Inogen in the 2nd quarter valued at approximately $336,000. Finally, Ameritas Investment Partners Inc. raised its position in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/06/inogen-inc-ingn-sets-new-52-week-high-at-98-78.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.